Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats

American Journal of Respiratory and Critical Care Medicine

Volumn 169, Issue 1, 2004, Pages 39-45

  Schermuly, Ralph T ^a   Kreisselmeier, Klaus P ^b   Ghofrani, Hossein A ^b   Yilmaz, Hüseyin ^b   Butrous, Ghazwan ^b   Ermert, Leander ^b   Ermert, Monika ^b   Weissmann, Norbert ^b   Rose, Frank ^b   Guenther, Andreas ^b   Walmrath, Dieter ^b   Seeger, Werner ^b   Grimminger, Friedrich ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NONE

Author keywords

Monocrotaline; Phosphodiesterase; Phosphodiesterase inhibitor; Pulmonary hypertension; Sildenafil

Indexed keywords

CYCLIC GMP; MONOCROTALINE; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTERIAL OXYGEN TENSION; ARTERIAL PRESSURE; ARTERY MUSCLE; ARTERY WALL; ARTICLE; BLOOD LEVEL; BLOOD VESSEL WALL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DYING; GAS EXCHANGE; HEART FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; TREATMENT OUTCOME;

EID: 10744233302     PISSN: 00030805     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200302-282oc     Document Type: Article

References (36)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-349.
2. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Buskila D, Dutz JP, Khostanteen I, Piper S. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-148.
3. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342.
4. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222.
5. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-522.
6. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
7. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84:E4.
8. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002;90:677-680.
9. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-2403.
10. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002;165:1098-1102.
11. Goldenberg MM. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998;20:1033-1048.
12. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999;29:297-310.
13. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 1998;157:351-370.
14. Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme aminoterminal domain. Biochim Biophys Acta 2001;1539:16-27.
15. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, Clarke WR. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 1998;158:279-288.
16. Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;281:L1051-L1057.
17. MacLean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997;283:619-624.
18. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002;137:1187-1194.
19. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26:194-201.
20. Huxtable RJ. Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacol Ther 1990;47:371-389.
21. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988;255:H1484-H1491.
22. Schermuly RT, Kreisselmeier KP, Yilmaz H, Butrous G, Samidurai A, Pullamsetti S, Ermert L, Weissmann N, Rose F, Walmrath D, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension and right heart hypertrophy [abstract]. Am J Respir Crit Care Med 2003;167:A824.
23. Schermuly RT, Weissmann N, Enke B, Ghofrani HA, Forssmann WG, Grimminger F, Seeger W, Walmrath D. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. Am J Respir Cell Mol Biol 2001;25:219-225.
24. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol 1981;240:H62-H72.
25. Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992;22:307-325.
26. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000;6:698-702.
27. Ono S, Voelkel NF. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol 1991;71:2483-2492.
28. Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3- diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997;282:1312-1318.
29. Sakuma F, Miyata M, Kasukawa R. Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats. Lung 1999;177:77-88.
30. Kodama K, Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther 1999;290:748-752.
31. Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 2002;121:1566-1571.
32. Castelain V, Chemla D, Humbert M, Sitbon O, Simonneau G, Lecarpentier Y, Herve P. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002;165:338-340.
33. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003;107:3230-3235.
34. Horstman DJ, Frank DU, Rich GF. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats. Anesth Analg 1998;86:74-81.
35. Maruyama J, Maruyama K, Mitani Y, Kitabatake M, Yamauchi T, Miyasaka K. Continuous low-dose NO inhalation does not prevent monocrotaline-induced pulmonary hypertension in rats. Am J Physiol 1997;272:H517-H524.
36. Gurjar MV, Sharma RV, Bhalla RC. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 1999;19:2871-2877.